| 
             
			
			 Researchers examined data from 74 previously published clinical 
			trials that randomly selected a total of more than 306,000 people to 
			take blood pressure drugs or placebo. 
			 
			Treatment to lower blood pressure only appeared to help prevent 
			heart disease and boost survival odds for people who started out 
			with systolic blood pressure above 140 mmHg. 
			 
			The exception was people with heart disease who took medication to 
			reduce blood pressure below 140 mmHg, who did have a lower risk of 
			cardiovascular events like heart attacks or strokes, the researchers 
			report online November 13 in JAMA Internal Medicine. 
			 
			“Our results support a very simple strategy where everyone with a 
			blood pressure above 140 mmHg should receive treatment, whereas most 
			people below that level will have no further benefit from additional 
			medications,” said study co-author Dr. Mattias Brunstrom of Umea 
			University in Sweden. 
			
			  
			“Patients with previous heart disease may benefit from lower blood 
			pressure goals, and an individual goal should be established 
			together with the patient´s physician,” Brunstrom said by email. 
			 
			Setting the right goal for blood pressure has been a matter of 
			intense debate in the medical community in recent years because 
			research to date has offered a mixed picture of which patients may 
			benefit from treatment, Brunstrom added. 
			 
			Complicating matters, many patients with dangerously high blood 
			pressure don’t take drugs to treat it or commit to lifestyle changes 
			that could achieve the same goal like improving their diet and 
			exercise habits. 
			 
			New recommendations announced this week at the American Heart 
			Association conference in Anaheim, California, set a systolic target 
			of 130 mmHg as a goal for lowering high blood pressure. For decades, 
			the goal had been 140 mmHg in the U.S., and this is still the target 
			in Europe. In Canada and Australia, however, the goal is 120 mmHg. 
			 
			“There is an ongoing controversy about setting strict guidelines 
			about blood pressure levels and in which setting it is safe or 
			justified to treat elevated blood pressure,” said Dr. Costantino 
			Iadecola, director of the Feil Family Brain and Mind Research 
			Institute at Weill Cornell Medicine in New York. 
			
            [to top of second column]  | 
            
             
  
            
			The results of the current study suggest that the right blood 
			pressure goal may not be one size fits all, Iadecola said. 
			 
			“The message here is that there is no universal number good for 
			everyone,” added Iadecola, who wasn’t involved in the study. 
			 
			When people had blood pressure of at least 160 mmHg, medication to 
			reduce it was associated with a 7% lower risk of death across all of 
			the studies in the analysis, as well as 22% lower odds of events 
			like heart attacks and strokes. 
			 
			Between 140 mmHg and 159 mmHg, the reduction in mortality risk was 
			similar but there was a smaller 12% decrease in the chances of 
			cardiovascular events like heart attacks or strokes. 
			Healthy people didn’t appear to benefit from medication if they 
			already had blood pressure below 140 mmHg. 
			 
			But with a history of heart disease and average blood pressure of 
			138 mmHg, medication was associated with a 10% lower risk of events 
			like heart attacks and strokes. Medication didn’t appear to 
			influence survival odds for these people, however. 
			 
			Because the study only examined lowering blood pressure with 
			medication, it’s not clear if the results would be the same for 
			other strategies such as changes in diet and exercise habits. 
			  
			
			  
			“We have no reason to think it should be any different with 
			lifestyle modifications, but the scientific evidence supporting that 
			lifestyle modifications cause less heart disease and stroke is 
			weaker,” Brunstrom said. 
			 
			SOURCE: http://bit.ly/2mnlVpg 
			 
			JAMA Intern Med 2017. 
			[© 2017 Thomson Reuters. All rights 
				reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  |